The Smallpox drugs in development market research report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Smallpox. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Smallpox and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Smallpox by 14 companies/universities/institutes. The top development phase for Smallpox is preclinical with 12 drugs in that stage. The Smallpox pipeline has 17 drugs in development by companies and two by universities/ institutes. Some of the companies in the Smallpox pipeline products market are: Tonix Pharmaceuticals Holding, State Research Center of Virology and Biotechnology VECTOR and GeoVax Labs.
The key targets in the Smallpox pipeline products market include 2019 Novel corona Virus Spike Glycoprotein, Alpha Tubulin, and Human SARS Coronavirus 2 Nucleoprotein.
The key mechanisms of action in the Smallpox pipeline product include Vaccinia Virus p37 Envelope Protein Inhibitor with one drug in Pre-Registration. The Smallpox pipeline products include eight routes of administration with the top ROA being Oral and nine key molecule types in the Smallpox pipeline products market including Small Molecule, and Recombinant Vector Vaccine.
Smallpox overview
Smallpox was an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain, and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antivirals and lifestyle modification.
For a complete picture of Smallpox’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
